Diligence memo · auto-generated · as of July 2, 2026
Astek Diagnostics, Inc.
Astek Diagnostics, Inc. looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
Astek Diagnostics, Inc. operates in Biotechnology, based in Halethorpe, MD, USA. One-hour antibiotic sensitivity testing
Sub-sector tags: medical-devices.
Capital & rounds (filed)filed
Astek Diagnostics, Inc. has raised $4.2M in disclosed capital across 6 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.4M on 2023-03-22.
Most recent recorded round closed around 2025-04-04.
Valuation (modeled)modeled
Provath models Astek Diagnostics, Inc. at approximately $2.4M (range $540K–$5.2M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.52× the median modeled value of Seed Biotechnology companies in 2025–2027 (99 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 8 months.
Last raise 15 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
The last round was 1.5× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 40% of Biotechnology peers (4293 compared).
Modeled value ranks above 6% of those peers.
Closest niche peers: Carna Inc., NRX Pharmaceuticals, Inc., Vicora, Inc., MH3D, Inc., Oral Genome Corp..
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.